Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.
NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago.
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.
NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues.
Nevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NVRO's continued technological innovations and business diversification plans raise optimism about the stock.